Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Fresenius Kabi agreed to buy a majority stake in the mAbxience division of Spain’s Insud Pharma to expand the generic drug unit’s business making cheaper versions of biotechnology products that have lost patent protection. Fresenius said Kabi also agreed to acquire Ivenix Inc., a maker of infusion therapies.


Biogen is selling the company’s nearly 50 percent stake in South Korea-based Samsung Bioepis for $2.3 billion.


Less than three months after Swedish Orphan Biovitrum AB (Sobi) agreed to be acquired by Advent International and GIC Special Investments for nearly $8 billion, the deal fell through after AstraZeneca withheld the company’s 8 percent stake from the buyout offer.

Less than two months after life sciences giant Bayer acquired N.C.-based gene therapy company AskBio, the healthcare company launched a cell and gene therapy platform within its pharmaceutical division.

Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.

Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.

TriNet, a leading global health research network optimizing clinical research to bring new therapies to market faster, announced global investment firm The Carlyle Group made a strategic growth investment and will acquire a majority stake in the company.

Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.